Is Rising Sales and a Swing to Net Loss Changing the Investment Case for LivaNova (LIVN)?

• LivaNova PLC reported its third quarter and nine-month 2025 earnings, showing sales growth to US$357.8 million for the quarter and US$1.03 billion for the nine months, compared to the same periods last year.
• While sales increased, the company saw quarterly net income decline and posted a net loss of US$273.4 million for the nine-month period, shifting from net income last year.
• We'll explore how the combination of higher sales and a substantial nine-month net loss reshapes LivaNova's investment outlook.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

LivaNova Investment Narrative Recap

To be a shareholder in LivaNova, you need to believe in its ability to grow sales through clinical innovation in neuromodulation and cardiopulmonary technologies, even as the company works to restore profitability. The recent report of higher nine-month sales but a sharp net loss puts the spotlight on margin pressures; while the revenue climb supports hopes for future procedure growth, the biggest short-term risk remains whether cost and reimbursement challenges could continue to weigh on earnings, a factor not materially amplified by this quarter’s results.

One of the most relevant developments is the August 18th commercial launch of the Essenz Perfusion System in China, a move designed to expand LivaNova’s global reach and capitalize on rising procedure volumes abroad. This expansion ties directly into the most important near-term catalyst: international adoption of advanced devices supporting recurring revenue and longer-term market share gains.

However, in contrast to expansion plans, the company’s exposure to global reimbursement scrutiny remains a detail investors should watch closely…

Read the full narrative on LivaNova (it's free!)

LivaNova's outlook anticipates $1.6 billion in revenue and $168.9 million in earnings by 2028. This scenario is predicated on a 6.4% annual revenue growth rate and a $380 million increase in earnings from the current $-211.3 million.

Uncover how LivaNova's forecasts yield a $65.00 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have produced fair value estimates for LivaNova ranging from US$65 to US$181, reflecting two different viewpoints. While multiple participants see upside potential, remember that ongoing global cost and margin risks could shape the company’s future return profile, explore these contrasting forecasts for a fuller picture.

Explore 2 other fair value estimates on LivaNova - why the stock might be worth just $65.00!

Build Your Own LivaNova Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your LivaNova research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free LivaNova research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LivaNova's overall financial health at a glance.

Searching For A Fresh Perspective?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com